Methionine enkephalin (Met-Enk) was evaluated for efficacy as an immune activator and potential therapeutic agent in influenza A/NWS/33 (H1N1) viral infections in female BALB/C mice. Influenza infection was induced intranasally with an approximate 90% lethal dose of virus and mice were treated intraperitoneally with doses of 10, 3 and 1 mg/kg/day, with treatments given 24 h pre-, 24 h post- and 72 h post-virus exposure. Splenocytes were assayed for natural killer cell (NK) and cytotoxic T lymphocyte (CTL) activity at time periods 76, 96 and 120 h post virus exposure. The 10 mg/kg dosage level significantly increased both CTL and NK activity at all time periods assayed. Other treatment schedules included single doses of 20, 10 and 3 mg/kg/day Met-Enk at either 24 h post- or 72 h post-virus exposure, with highly significant increases in NK and CTL activity noted after the latter treatment. The results of this study demonstrate the immunomodulatory effects of Met-Enk on NK and CTL in influenza infected mice and suggest a potential for therapeutic applications.

Download full-text PDF

Source
http://dx.doi.org/10.3109/08923979509019754DOI Listing

Publication Analysis

Top Keywords

ctl activity
12
methionine enkephalin
8
natural killer
8
killer cell
8
cell cytotoxic
8
cytotoxic lymphocyte
8
potential therapeutic
8
doses mg/kg/day
8
post- post-virus
8
post-virus exposure
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!